NorthWest Biotherapeutics Inc (NWBO)

[iclight]

It's a 21 patient open label P1 safety trial with secondary efficacy endpoints. When the first 3 enrolled patients show promise it's something to write home about.

And they were treated last year, not in 2012 when the DCVax trials first patients were treated. Let me know how DCVax's first 3 patients fared.

A 72-year-old man was treated with a single infusion of CAR-TEAM cells. Two days after receiving CAR-TEAM cells, an MRI showed a decrease in the tumor’s size by 18.5 percent. By day 69, the tumor had decreased by 60.7 percent, and the response was sustained for over 6 months.

That's double a partial response based on Recist criteria.

The Direct trial showed ZERO ORR.